Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-12-16-Speech-2-266"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-12-16"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20031216.6.2-266"2
lpv:hasSubsequent	lp_eu:2003-12-16-Speech-2-2672
lpv:speaker	lp:Alexander de Roo2
lpv:spokenAs	unknown; GroenLinks (1999-07-20--2004-07-19)3 substitute; AGRI (2002-01-17--2004-07-19)3 member; G/EFA (1999-07-20--2004-07-19)3 member; Delegation to the EU-Cyprus Joint Parliamentary Committee (2002-02-07--2004-04-30)3 vice-chair; Committee on the Environment, Public Health and Consumer Policy (2002-01-22--2004-07-19)3
lpv:translated text	"Mr President, my warmest congratulations to my fellow MEPs Mrs Müller and Mrs Grossetête, and also to the brilliant Commissioner Liikanen and the Italian Presidency. We have reached a good compromise: eight years for generic medicinal products, to begin with: the European Parliament achieved this. The ten years has been dropped. The Dutch Government voted against the common position since it would mean an extra EUR 160 million expenditure per year in the Netherlands alone. At first reading, the European Parliament reached a good compromise of between six and eight years. We have held on to this, and have also been able to push it through in the face of opposition from the Council and the Commission. The centralised procedure via the EMEA in London is increasingly becoming the norm for an increasing number of medicinal products. That is a good thing. In this regard, too, Parliament has put its stamp on the legislation in no uncertain terms. We should have liked more, but the compromise is acceptable. It was very important to us, the Group of the Greens/European Free Alliance, to incorporate the environmental effects of medicinal products into that Community legislation. REACH does not do this – a small error on the part of our brilliant commissioner. That deficiency has now been remedied, however. In the case of veterinary medicinal products, negative environmental effects can even lead to a blockade. That is not the case with human medicinal products, but negative effects will indeed be taken into account. I am happy that the Commission has spoken out on Doha and stated that it will present legislation in early 2004. We shall hold the Commission to this. American advertising of medicinal products is and remains banned. We in the Verts/ALE Group welcome this. We shall have to discuss later on how provision of information to patients can be improved via websites and telephone helplines, and indeed that is the crux of the matter. Direct patient reporting did not make it. Member States can develop this further, however, and some of them will do so, and the subject will return to the agenda later. The line between food supplements and medicinal products is not sufficiently well defined. Let us hope that the Commission will conduct an accommodating policy on this. Homeopathic medicinal products did not make it. We in the Verts/ALE Group shall continue to fight for these."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph